CCDC91

Across TCGA pan-cancer cohorts, CCDC91 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CCDC91 data layer compared with 17 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CCDC91 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC91 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LUAD, LSCC, and GBM are the cancer types where CCDC91 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.653	0.980	<.001	62	view →
LSCC	DFS	Median	All	0.976	0.891	.003	13	view →
GBM	DFS	Tertile	All	0.553	0.843	.006	6	view →
PDAC	OS	Tertile	All	0.996	0.736	.013	4	view →
CCRCC	DFS	Median	All	0.659	0.819	.035	2	view →
HNSC	OS	Quartile	III,IV	0.764	0.537	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CCDC91–LUAD (DFS)

Open the LUAD breakdown →